Certified Professional Resume Writing Services The following companies might be the next big movers and winners of the 2011 year. With significant milestones achieved and unique products, they are leaders in their respective fields and are ready to deliver shareholder value in the coming months.
Non Plagiarized Us Writers Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin’s lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.
Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma and mantle cell lymphoma. It is also developing an automated cell culture instrument. The company also sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies.
Discount Code For Custom Essay Next coming catalyst event for INVO Bioscience might come from Asia, with the expected Class II medical device classification for the INVOcell in China.
In August 10th, INVO Bioscience along with his distribution partner The Progressive Group, one of the larger med device and equipment distributors in this area, have started the registration process with Chinese FDA authorities.
“During the third quarter of 2010, our focus was on preparation of the 5 modules that make up the NDA submission for Marqibo(R)” stated Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. “An analysis of data from the Menadione Topical Lotion Phase 1 program showed that it was generally safe and well tolerated. In addition, the dose limiting toxicity and apparent maximum tolerated lotion strength were identified. Our strategy is to seek a partner to enhance and accelerate the continued development of Menadione Topical Lotion.
http://www.umass.lambdaphiepsilon.com/i-need-a-wife-essay/ I Need A Wife Essay The presentation revealed that CECOLFES produced clinical pregnancy rates of 43% per INVOcell cycle and a 48% clinical pregnancy rate when an embryo has been transferred in the cycle.
That might be a good time to look again at Hana Biosciences, as they have many catalysts and news to release before the end of 2010 that should drive shareholder value:
– Rolling NDA filling for Marqibo in Adult ALL (that means a PDUFA date and the classic run-up period)
Where Is The Best To Buy Cheap Essays Online – Top-line Menadione Topical Lotion proof-of-concept data
– Initiate Phase 2 Menadione Topical Lotion trial
Buy Sony DVD Architect Pro 5 oem – Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma with an estimated primary completion date of December 2010 (Final data collection date for primary outcome measure)
2011 might also be a very good year for Hana Biosciences, with the potential approval of Marqibo in Adult ALL and the start of Phase III studies for other indication with Marqibo ($5B market).
http://envsci.uprrp.edu/?dissertation-writing-services-sri-lanka-952 Dissertation Writing Services Sri Lanka 952 The actual market cap of $2M is ridiculous considering that INVO Bioscience is becoming a strong and recognized company in the infertility field. With a unique device product already CE mark and an international distribution network in place, it would worth already at the very least 10 times the actual market cap! The Zack’s analyst has an outperform recommendation with a target price of $0.25.
We believe that major news are going to be released, we are awaiting for the clinical trial result in Columbia and have been told that it might be surprising and big, also a positive answer from the Federal R&D Tax Credit would be a very big news for the company and investors. The work already accomplished by the company is amazing and while it is taking more time than anticipated to increase revenue and resulting income, 2011 should improve dramatically for INVO Bioscience. With an estimated 150 million infertile couples worldwide, at the current market value of only $2M, we believe that this is dramatically underappreciated by Wall Street, recent developments and coming news should easily push up the price above the $0.20 range again.
In this piece I will analyze three essential components and share my thoughts with you as to why they are crucial in this context and to US Wireless Online (PINK:UWRL) investors. Recent News Release U.S. Wireless Online, Inc. (UWRL) Comments on Recent Stock Price Volatility (Source: http://yhoo.it/9rbRlT) HENDERSON, NV, U.S. Wireless Online, Inc. (UWRL.PK) today […]
Optumrx Prior Authorization Cialis AQUAGOLD INTERNATIONAL INC. (PINK: AQUI) is a global distributor of premier Canadian spring water products. Since the company’s inception, the South-Pacific region has been the focus of its operations. The area’s extremely fast growing demands and the creation of Aquagold Asia, a Chinese corporation, have allowed Aquagold International to establish a prominent position in the […]